Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1965 1
1972 1
1986 1
1988 1
1997 2
2006 1
2008 2
2010 2
2011 2
2012 2
2013 4
2014 6
2015 6
2016 3
2017 4
2018 1
2019 5
2020 4
2021 5
2022 3
2023 1
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

48 results

Results by year

Filters applied: . Clear all
Page 1
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.
Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao LL, Miao Y, Adedokun OJ, Sands BE, Hanauer SB, Vermeire S, Targan S, Ghosh S, de Villiers WJ, Colombel JF, Tulassay Z, Seidler U, Salzberg BA, Desreumaux P, Lee SD, Loftus EV Jr, Dieleman LA, Katz S, Rutgeerts P; UNITI–IM-UNITI Study Group. Feagan BG, et al. N Engl J Med. 2016 Nov 17;375(20):1946-1960. doi: 10.1056/NEJMoa1602773. N Engl J Med. 2016. PMID: 27959607 Free article. Clinical Trial.
Vedolizumab as induction and maintenance therapy for Crohn's disease.
Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, Fox I, Rosario M, Sankoh S, Xu J, Stephens K, Milch C, Parikh A; GEMINI 2 Study Group. Sandborn WJ, et al. N Engl J Med. 2013 Aug 22;369(8):711-21. doi: 10.1056/NEJMoa1215739. N Engl J Med. 2013. PMID: 23964933 Free article. Clinical Trial.
A new ELISA for quantification of brassinosteroids in plants.
Pradko AG, Litvinovskaya RP, Sauchuk AL, Drach SV, Baranovsky AV, Zhabinskii VN, Mirantsova TV, Khripach VA. Pradko AG, et al. Among authors: baranovsky av. Steroids. 2015 May;97:78-86. doi: 10.1016/j.steroids.2014.08.022. Epub 2014 Sep 6. Steroids. 2015. PMID: 25201263
Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis.
Andus T, Kocjan A, Müser M, Baranovsky A, Mikhailova TL, Zvyagintseva TD, Dorofeyev AE, Lozynskyy YS, Cascorbi I, Stolte M, Vieth M, Dilger K, Mohrbacher R, Greinwald R; International Salofalk Suppository OD Study Group. Andus T, et al. Among authors: baranovsky a. Inflamm Bowel Dis. 2010 Nov;16(11):1947-56. doi: 10.1002/ibd.21258. Inflamm Bowel Dis. 2010. PMID: 20310020 Clinical Trial.
A facile method for the preparation of 7,8-dihydro-4H-chromene-4,5(6H)-diones as non-aromatic cycle A analogs of isoflavones and their evaluation as antiproliferative agents.
Rubinov DB, Zinovich VG, Scherbakov AM, Chukarina TV, Sorokin DV, Ohurtsova SE, Shafranovskaya EV, Laptsevich VV, Mikhaylova AL, Bogdanov FB, Baranovsky AV, Puzanau RM, Pakhadnia YG, Lakhvich FA, Piven YA. Rubinov DB, et al. Among authors: baranovsky av. Bioorg Chem. 2025 Oct;165:108960. doi: 10.1016/j.bioorg.2025.108960. Epub 2025 Sep 5. Bioorg Chem. 2025. PMID: 40939536
Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial.
Vermeire S, Schreiber S, Petryka R, Kuehbacher T, Hebuterne X, Roblin X, Klopocka M, Goldis A, Wisniewska-Jarosinska M, Baranovsky A, Sike R, Stoyanova K, Tasset C, Van der Aa A, Harrison P. Vermeire S, et al. Among authors: baranovsky a. Lancet. 2017 Jan 21;389(10066):266-275. doi: 10.1016/S0140-6736(16)32537-5. Epub 2016 Dec 15. Lancet. 2017. PMID: 27988142 Clinical Trial.
48 results